PBS3/B7/24/2015

The Nano5-FU project is being carried out by NanoVelos S.A. as the leader of a consortium in collaboration with two academic partners: the Warsaw University of Technology and the Medical University of Warsaw. The aim of the project is to develop, optimize, and complete in vitro and in vivo studies of NanoVelos’ proprietary polysaccharide-based nanoparticle containing 5-fluorouracil (5-FU), one of the most widely used chemotherapeutic agents. 5-FU is used, among others, in the treatment of colorectal cancer. Its major drawbacks include severe side effects and a very short half-life in the body—only approximately 20 minutes.

The application of NanoVelos technology for targeted 5-FU therapy will enable a significant extension of the drug’s half-life. The unique mechanism of action of NanoVelos nanoparticles is based on active targeting of cancer cells by exploiting the Warburg effect and enabling controlled drug release exclusively within tumor cells. This approach is expected to drastically reduce side effects and significantly enhance the therapeutic efficacy of 5-FU in cancer treatment.

Project value: PLN 1,547,377.00

Funding amount: PLN 1,282,424.00